Company Analysis
Sign in

Aardvark Therapeutics, Inc. (AARD)

Nasdaq: AARD · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.1
◀ Past 4.4● Present 5.5▶ Future 5.2
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

7 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Aardvark Therapeutics, Inc.’s names, not what it holds today.

Patents granted
7
7 utility, 1976 to Dec 31, 2025
Granted in 2025
6
in the last year the record reads
Applications published
14
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Aardvark Therapeutics, Inc. its own name
US, as the owner printed on each patent
7 granted
12 published
AARDVARK THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 30, 202512,427,125Method for treating SARS and treating or preventing ARDSPharmaceuticalsAardvark Therapeutics, Inc.
Sep 16, 202512,414,934Combination therapiesPharmaceuticalsAardvark Therapeutics, Inc.
Jun 17, 202512,329,739Isoflavonoid compounds and methods for the treatment of cancerPharmaceuticalsAardvark Therapeutics, Inc.
Jun 3, 202512,318,364Isoflavonoid compositions and methods for the treatment of cancerPharmaceuticalsAardvark Therapeutics, Inc.
Apr 8, 202512,268,660Oral pharmaceutical formulations of bitter compounds for pulmonary hypertensionPharmaceuticalsAardvark Therapeutics, Inc.
Jan 21, 202512,201,593Oral pharmaceutical formulations of bitter compounds for asthmaPharmaceuticalsAardvark Therapeutics, Inc.
Nov 17, 202010,835,505Oral pharmaceutical formulation for weight loss, diabetes and related disordersPharmaceuticalsAardvark Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 20, 20252025/0352498PHARMACEUTICAL FORMULATIONS CONTAINING PHENYLBUTYRATE AND METHODS THEREOFPharmaceuticalsAardvark Therapeutics, Inc.
Feb 13, 20252025/0049924Abuse-Deterrent Pharmaceutical Composition with Aversion PropertiesPharmaceuticalsAardvark Therapeutics, Inc.
Nov 28, 20242024/0390306Monohydrate Salt of Denatonium AcetatePharmaceuticalsAardvark Therapeutics, Inc.
Nov 7, 20242024/0366505Liquid Resin Extended-Release Oral Naltrexone Formulation for Treating Autism-Related DisordersPharmaceuticalsAardvark Therapeutics, Inc.
Jul 4, 20242024/0216476COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUNDPharmaceuticalsAardvark Therapeutics, Inc.
Mar 28, 20242024/0100001DENATONIUM SALT FOR USE IN PREVENTING, PREVENTING PROGRESSION AND TREATING FATTY LIVER DISEASESPharmaceuticalsAardvark Therapeutics, Inc.
May 18, 20232023/0149328Method for Treating SARS and Treating or Preventing ARDSPharmaceuticalsAardvark Therapeutics, Inc. · patent 12,427,125 granted from it
Apr 20, 20232023/0121611Monohydrate Salt of Denatonium AcetatePharmaceuticalsAardvark Therapeutics, Inc.
Mar 30, 20232023/0096528Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disordersPharmaceuticalsAardvark Therapeutics, Inc.
Sep 8, 20222022/0280457ORAL PHARMACEUTICAL IMMEDIATE RELEASE COMPOSITION AND METHOD OF TREATMENT FOR WEIGHT LOSSPharmaceuticalsAardvark Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 6.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AARD · research, not advice